Skip to main content
Premium Trial:

Request an Annual Quote

Genedata, Bayer Schering Collaborate on Biologics Data Management

NEW YORK (GenomeWeb News) – Genedata and Bayer Schering Pharma have entered into a multi-year collaboration to develop and use Genedata's Biologics Data Platform at Bayer Schering locations, the companies said today.

Under the agreement, BDP will support biologics data management and analysis at Bayer Schering R&D sites in Europe and the US, which are developing protein-based therapeutics for diseases such as cancer, hemophilia, and multiple sclerosis.

Financial terms of the agreement were not disclosed.

BDP is a shared data-storage and data-exchange platform that can synchronize Bayer Schering's activities from biologics screening through production, the companies said.

Developed for both antibody-based and other protein therapeutics, BDP supports informatics tasks such as library generation, laboratory logistics, and biologics registration and analytics.

"The Biologics Data Platform is an important system for our daily operations as it makes the highly interconnected biologics R&D processes more efficient," Heiner Apeler, director of molecular and antibody biology at Bayer Schering, said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.